Peptide manufacturer Mytide Therapeutics names Martina Diekmann as CEO
06 Apr 2023
Executive ChangePDC
Massachusetts-based peptide manufacturer Mytide Therapeutics has named a member of its advisory board, Martina Diekmann, as its new CEO.
Diekmann will be taking over for Mytide’s founder Dale Thomas, who has served as CEO since 2018. Thomas will move to the chief technology officer spot, a release said. Diekmann joined the advisory board in 2022 and has previously served as a CEO of peptide CRO and CDMO Vivitide. According to her LinkedIn profile, she also held several management roles at companies such as Bachem and Solvias.
Preview
Source: EndPoints
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 164,300+ biopharma pros reading Endpoints daily — and it's free.
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.